A Phase 1 interventional study of pridopidine (90 mg) in Health Volunteers, Huntington Disease, sponsored by Prilenia. Completed at 1 site in Germany. Open to male participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Prilenia · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Huntington Disease with a site in Germany — 7 open to participants now, 9 under way, 3 of them phase 3. Huntington Disease · Germany.
Among the 44 studies in Huntington Disease with a site in Germany, this one is the 35th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 5 in phase 1, and was the 22nd registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →7 of the 44 studies in Huntington Disease with a site in Germany are open now. Recruiting first, the newest first:
Prilenia · Sites in Germany, United States, Belgium and 9 more countries
Ages 23–65
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in Germany, United States, Argentina and 7 more countries
Ages 25+
Alnylam Pharmaceuticals · Sites in Germany, Canada, United Kingdom
Ages 25–70
Vico Therapeutics B. V. · Sites in Germany, Denmark, France and 3 more countries
Ages 25–60
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 25 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 7
First in 2004; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 95 across the 37 interventional studies, 574 across the 7 observational. Of the 33 that completed or were terminated, 21 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 44 have an industry lead sponsor. The 10 most frequent:
Prilenia is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Prilenia has 6 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Huntington Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02855476University College, LondonHDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Huntington Disease with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R (optional) in the living human brain. No formal statistical analysis will be conducted
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with Huntington's disease (HD): diagnosis of HD and with an onset of HD after 18 years of age
Exclusion Criteria:
Treatment with any product within 6 weeks of screening or patients planning to participate in another clinical study assessing any investigational product during the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pridopidine (TV-7820) capsules
Drug: pridopidine (90 mg)
single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
Sigma-1 Receptor Occupancy
Receptor occupancy of pridopidine to Sigma-1 receptors (S1R) in the brain was assessed from Positron Emission Tomography (PET) imaging with (S)-(-)-\[18F\]fluspidine
Time frame: 2 hours after oral administration of pridopidine
Maximum Plasma Concentration of Pridopidine
Maximum plasma concentration of pridopidine based on noncompartmental analysis
Time frame: PK sampling 1 h before pridopidine dosing, and 5, 15, 30, 45, 60 min, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h after dosing.
Time to Reach Maximum (Peak) Concentration (Tmax)
Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.
Time frame: PK sampling 1 h before pridopidine dosing, and 5, 15, 30, 45, 60 min, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h after dosing.
Dopamine-2 Receptor Occupancy
RO of D2 (Dopamine-2) at 2 hours after oral administration of pridopidine (90 mg dose level) was investigated in 4 healthy volunteers using \[18F\]fallypride
Time frame: 2 h after pridopidine dosing
Healthy volunteers (HV) and patients with Huntington Disease (HD) were enrolled. The first participant was enrolled on 22 March 2017; the last subject completed the study on 09 February 2018.
| Milestone | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + Fallypride; HV | Cohort 0: (S)-(-)-FPD, HV |
|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 1 | 3 | 2 | 1 | 1 | 3 | 4 | 3 |
| Completed | 3 | 1 | 3 | 2 | 1 | 1 | 3 | 4 | 2 |
| Not completed | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Receptor occupancy of pridopidine to Sigma-1 receptors (S1R) in the brain was assessed from Positron Emission Tomography (PET) imaging with (S)-(-)-\[18F\]fluspidine
| percentage of receptor occupancy | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD |
|---|---|---|---|---|---|---|---|
| Sigma-1 Receptor Occupancy | 91.21 (88.82 to 95.67) | 87.19 (87.19 to 87.19) | 86.67 (84.06 to 89.24) | 77.96 (76.75 to 79.16) | 41.77 (41.77 to 41.77) | 17.55 (17.55 to 17.55) | 87.37 (80.36 to 93.23) |
Maximum plasma concentration of pridopidine based on noncompartmental analysis
| ng/mL | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + FPD; HV |
|---|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration of Pridopidine | 552 (496 to 614) | 307 (307 to 307) | 147 (117 to 184) | 25.9 (16.1 to 41.8) | 2.90 (2.90 to 2.90) | 1.33 (1.33 to 1.33) | 764 (666 to 877) | 452 (244 to 724) |
Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.
| hours | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + Fallypride; HV |
|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum (Peak) Concentration (Tmax) | 1.97 (1.50 to 3.00) | 1.98 (1.98 to 1.98) | 1.00 (0.75 to 1.50) | 1.00 (0.75 to 1.50) | 1.98 (1.98 to 1.98) | 1.97 (1.97 to 1.97) | 1.00 (0.50 to 1.62) | 2.26 (1.00 to 5.02) |
RO of D2 (Dopamine-2) at 2 hours after oral administration of pridopidine (90 mg dose level) was investigated in 4 healthy volunteers using \[18F\]fallypride
| percent volume/volume | B: Cohort 4: P90 + FPD; HV |
|---|---|
| Dopamine-2 Receptor Occupancy | 3.34 ± 2.05 |
Collected over From signing of the informed consent through to 7 days after the last administration of study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A: Cohort 1: P90 + (S)-(-)-FPD; HV | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| A: Cohort 2: P45 + (S)-(-)-FPD; HV | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| A: Cohort 3: P5 + (S)-(-)-FPD; HV | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| A: Cohort 7: P1 + (S)-(-)-FPD; HV | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| A: Cohort 6; P90 + (S)-(-)-FPD; HD | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| B: Cohort 4: P90 + Fallypride; HV | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Cohort 0: (S)-(-)-FPD, HV | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + Fallypride; HV | Cohort 0: (S)-(-)-FPD, HV |
|---|---|---|---|---|---|---|---|---|---|
| Catheter site hematomaGeneral disorders | 0/5 | 0/1 | 0/3 | 0/2 | 0/1 | 0/1 | 0/3 | 0/4 | 3/3 |
| Haemoglobin decreasedInvestigations | 2/5 | 1/1 | 0/3 | 0/2 | 0/1 | 0/1 | 0/3 | 0/4 | 0/3 |
| VomitingGastrointestinal disorders | 0/5 | 0/1 | 0/3 | 0/2 | 0/1 | 0/1 | 0/3 | 1/4 | 1/3 |
| Catheter site painGeneral disorders | 0/5 | 0/1 | 0/3 | 0/2 | 0/1 | 0/1 | 0/3 | 0/4 | 1/3 |
| Catheter site paraesthisiaGeneral disorders | 0/5 | 0/1 | 0/3 | 0/2 | 0/1 | 0/1 | 0/3 | 0/4 | 1/3 |
| Vessel puncture site haematomaGeneral disorders | 0/5 | 0/1 | 0/3 | 0/2 | 0/1 | 0/1 | 0/3 | 0/4 | 1/3 |
| ConjunctivitisInfections and infestations | 0/5 | 0/1 | 0/3 | 0/2 | 0/1 | 0/1 | 1/3 | 0/4 | 0/3 |
| NasopharyngitisInfections and infestations | 0/5 | 0/1 | 0/3 | 0/2 | 0/1 | 0/1 | 1/3 | 0/4 | 0/3 |
| Skin abrasionInjury, poisoning and procedural complications | 0/5 | 0/1 | 1/3 | 0/2 | 0/1 | 0/1 | 0/3 | 0/4 | 0/3 |
| Sports injuryInjury, poisoning and procedural complications | 0/5 | 0/1 | 1/3 | 0/2 | 0/1 | 0/1 | 0/3 | 0/4 | 0/3 |
All subjects/patients enrolled
| Age, Continuous(years) | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + Fallypride; HV | Cohort 0: (S)-(-)-FPD, HV | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Median | 28.0 (27 to 30) | 26.0 (26 to 26) | 25.0 (25 to 28) | 27.5 (27 to 28) | 30 (30 to 30) | 25.0 (25 to 25) | 40.0 (32 to 58) | 28.0 (25 to 35) | 29.0 (25 to 30) | 28 (25 to 58) |
| Sex: Female, Male(Participants) | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + Fallypride; HV | Cohort 0: (S)-(-)-FPD, HV | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 1 | 3 | 2 | 1 | 1 | 3 | 4 | 3 | 23 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + Fallypride; HV | Cohort 0: (S)-(-)-FPD, HV | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| White | 5 | 1 | 3 | 2 | 1 | 1 | 3 | 4 | 2 | 22 |
| Black/African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | A: Cohort 1: P90 + (S)-(-)-FPD; HV | A: Cohort 2: P45 + (S)-(-)-FPD; HV | A: Cohort 2: P22.5 + (S)-(-)-FPD; HV | A: Cohort 3: P5 + (S)-(-)-FPD; HV | A: Cohort 7: P1 + (S)-(-)-FPD; HV | A: Cohort 7: P0.5 + (S)-(-)-FPD; HV | A: Cohort 6; P90 + (S)-(-)-FPD; HD | B: Cohort 4: P90 + Fallypride; HV | Cohort 0: (S)-(-)-FPD, HV | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Germany | 5 | 1 | 3 | 2 | 1 | 1 | 3 | 4 | 3 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Feb 2018, 9 months.
Results were first posted in Nov 2021, 3 years 9 months after primary completion.
Of 19 phase 1 interventional studies under Huntington Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Prilenia